Tissue factor (TF), the initiator of the extrinsic coagulation pathway, is upregulated in cancer cells and the complex of TF with its ligand coagulation factor VIIa (FVIIa) contributes to cancer- associated thrombosis and activation of the host hemostatic system in metastasis. In addition, cancer cell signaling of the TF-FVIIa complex, in cooperation with the TF cytoplasmic domain, promotes tumor progression in spontaneous murine and human xenograft models by activating proangiogenic cell signaling of the G protein-coupled protease activated receptor (PAR) 2. This pathway can be targeted to attenuate tumor growth in preclinical tumor models. In this renewal application, we address unresolved major questions on the roles of the TF pathway in tumor biology, utilizing newly developed genetic and pharmacological approaches.
Aim 1 utilizes an integrin binding-impaired mutant of FVIIa to dissect integrin-dependent and -independent signaling of the TF-FVIIa complex. In addition, characterization of a novel mouse model carrying cleavage-insensitive PAR2 will provide the first definitive distinction of proteolytic and cleavage- independent bystander roles of PAR2 in tumor progression and metastasis.
Aim 2 addresses the origin of upstream coagulation proteases that promote tumor growth by activating cancer cell-expressed protease receptors and delineates the respective contributions of FVIIa and FXa to cancer cell PAR2 activation.
In Aim 3, the specific functions of TF splice variants in angiogenesis are further elucidated with novel genetic and pharmacological tools. The proposed studies are expected to yield valuable new insights into potential therapeutic approaches to block tumor promoting signaling of the coagulation pathway.
The proposed genetic and pharmacological experiments will critically evaluate existing concepts of TF proteolytic and integrin signaling pathways and advance the paradigm of paracrine communication between tumor cells and the tumor microenvironment. The delineation of coagulation-independent effects of the upstream coagulation cascade has profound implications for assessing the potential therapeutic benefits of new protease-specific anticoagulants in halting tumor progression and attenuating angiogenesis.
|Gur-Cohen, Shiri; Kollet, Orit; Graf, Claudine et al. (2016) Regulation of long-term repopulating hematopoietic stem cells by EPCR/PAR1 signaling. Ann N Y Acad Sci 1370:65-81|
|Ruf, Wolfram; Rothmeier, Andrea S; Graf, Claudine (2016) Targeting clotting proteins in cancer therapy - progress and challenges. Thromb Res 140 Suppl 1:S1-7|
|Liang, Hai Po H; Kerschen, Edward J; Basu, Sreemanti et al. (2015) Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood 126:2415-23|
|Gur-Cohen, Shiri; Itkin, Tomer; Chakrabarty, Sagarika et al. (2015) PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells. Nat Med 21:1307-17|
|Ruf, Wolfram; Schaffner, Florence (2014) Role of the protein C receptor in cancer progression. Thromb Res 133 Suppl 2:S85-9|
|Sluka, Susanna H M; Akhmedov, Alexander; Vogel, Johannes et al. (2014) Alternatively spliced tissue factor is not sufficient for embryonic development. PLoS One 9:e97793|
|Yokota, N; Zarpellon, A; Chakrabarty, S et al. (2014) Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. J Thromb Haemost 12:71-81|
|Schaffner, Florence; Yokota, Naho; Carneiro-Lobo, Tatiana et al. (2013) Endothelial protein C receptor function in murine and human breast cancer development. PLoS One 8:e61071|
|Reinhardt, Christoph; Bergentall, Mattias; Greiner, Thomas U et al. (2012) Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling. Nature 483:627-31|
|Schaffner, Florence; Yokota, Naho; Ruf, Wolfram (2012) Tissue factor proangiogenic signaling in cancer progression. Thromb Res 129 Suppl 1:S127-31|
Showing the most recent 10 out of 31 publications